Results for:(17 found)
Tue 11:04 AM on Top StocksBy TheStreet.com Staff

Valeant Pharmaceuticals has teamed up with activist investor Bill Ackman and Pershing Square Capital Management for a $47 billion deal to acquire Botox maker Allergan.

Mon 5:29 PM on Top StocksBy MSN Money Partner

An activist investor and corporate acquirer may be teaming up to make an offer for Allergan.

Oct 3, 2013 8:24AM on Top StocksBy StreetAuthority

If you've ever wanted to invest alongside the best hedge funds, these simple investments allow you to do just that.

Sep 17, 2013 10:57AM on Top StocksBy MSN Money Partner

Kellogg is downgraded to 'underweight,' and Valeant is initiated with a 'conviction buy.'

Aug 8, 2013 10:16AM on Top StocksBy MSN Money Partner

Crocs is downgraded to 'underperform,' and Baxter is reinstated with a 'conviction buy.'

May 31, 2013 12:04PM on Top StocksBy MSN Money Partner

CIBC is downgraded to 'neutral,' and Tiffany is initiated with an 'outperform.'

May 28, 2013 1:53PM on Top StocksBy MSN Money Partner

Stocks are up about 1% as reports show consumer confidence climbs and home prices advance.

May 28, 2013 11:39AM on Top StocksBy MSN Money Partner

The Canadian pharmaceutical company sees synergies with its existing ophthalmology businesses.

Tags: VRX

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More